EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Multi-Omics and Machine Learning Analyses Reveal PIK3CG, PRKCD, and TRIM22 as Potential Markers of Poor Prognosis and Immune Activation in Glioblastoma

Myung-Hoon Han iD, Yung-Kyun Noh iD, Hyunkee Kim iD, Kyu Shik Kim iD, Dong-Hoon Kim iD, Un Suk Jung iD, Kyung Suk Lee iD, Mi Jung Kwon iD, Seoung Wan Chae iD, Kyueng-Whan Min iD

Journal of Korean Medical Science · 2026

DOI: 10.3346/jkms.2026.41.e130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Korean Medical Science, 2026. Verfasst von Myung-Hoon Han und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea. Hauptthemen laut MEDLINE: Glioblastoma, Biomarkers, Tumor, Class I Phosphatidylinositol 3-Kinases, Machine Learning. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CN Research Foundation for Rare Disease, IITP/MSIT, Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Glioblastoma (GBM) is one of the most aggressive brain tumors with a poor prognosis despite current treatment modalities. This study aimed to identify genes whose high expression is paradoxically associated with both poor survival and enhanced immune activity, as potential targets for combination chemotherapeutic and immunotherapeutic strategies. METHODS: Transcriptomic data from patients with central nervous system World Health Organization (WHO) grade IV gliomas (based on the 2016 WHO classification) were analyzed, using datasets from The Cancer Genome Atlas (525 cases), the Chinese Glioma Genome Atlas (250 cases), and the Genotype-Tissue Expression (1,152 normal samples). We initially screened 12,041 genes, prioritizing those showing a paradoxical association with prognosis and immune activation. Key genes were selected through rank statistics, machine-learning-based survival modeling, and pathway network analysis. Further subgroup validation was performed using only isocitrate dehydrogenase (IDH)-wildtype GBM cases, in line with the 2021 WHO classification. RESULTS: Among the 12,041 candidate genes analyzed, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (PIK3CG), protein kinase C delta type (PRKCD), and tripartite motif-containing protein 22 (TRIM22) were identified as key biomarkers whose elevated expression was significantly associated with poorer overall and disease-specific survival in IDH-wildtype GBM. These genes also correlated with enhanced immune activity, including increased tumor-infiltrating lymphocytes and elevated expression of programmed death-ligand 1. Pathway network analysis revealed indirect associations with critical immune markers such as CD8A and CD4, suggesting potential immunomodulatory functions. Additionally, differential gene expression and disease ontology analyses demonstrated their relevance across various cancer types. Drug sensitivity profiling using the Genomics of Drug Sensitivity in Cancer database identified AGI-6780, linsitinib, and Nutlin-3a as potential therapeutic agents targeting these genes. CONCLUSION: This study identifies PIK3CG, PRKCD, and TRIM22 as potential biomarkers and therapeutic targets in IDH-wildtype GBM. Their paradoxical association with poor survival and immune activation may inform personalized treatment strategies that combine conventional chemotherapy with immune-based therapies. While our findings are robust across both mixed and IDH-wildtype-focused cohorts, further mechanistic validation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesMachine LearningBrain NeoplasmsHumansPrognosisGene Expression Regulation, NeoplasticMultiomicsGene Expression ProfilingIsocitrate DehydrogenaseClass Ib Phosphatidylinositol 3-Kinase

Stichwörter der Autor:innen

BiologyComputationalGlioblastomaImmunitySurvival

Substanzen

Biomarkers, TumorClass I Phosphatidylinositol 3-KinasesPIK3CD protein, humanPIK3CG protein, humanIsocitrate DehydrogenaseClass Ib Phosphatidylinositol 3-Kinase

Autor:innen und Institutionen

  • Department of Neurosurgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
  • Department of Computer Science, Hanyang University, Seoul, Korea.
  • School of Computational Sciences, Korea Institute for Advanced Study, Seoul, Korea.
  • Department of Neurology, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea.
  • CardiOmics Program, Center for Heart and Vascular Research, Division of Cardiovascular Medicine, Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, USA.
  • Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Myung-Hoon Han, Yung-Kyun Noh, Hyunkee Kim, Kyu Shik Kim, Dong-Hoon Kim, Un Suk Jung, Kyung Suk Lee, Mi Jung Kwon, Seoung Wan Chae, Kyueng-Whan Min

Förderung

  • CN Research Foundation for Rare Disease
  • IITP/MSIT
  • Korea Health Industry Development Institute

Zitieren

APA

Han, M. H., Noh, Y. K., Kim, H., Kim, K. S., Kim, D. H., Jung, U. S., Lee, K. S., Kwon, M. J., Chae, S. W., & Min, K. W. (2026). Multi-Omics and Machine Learning Analyses Reveal PIK3CG, PRKCD, and TRIM22 as Potential Markers of Poor Prognosis and Immune Activation in Glioblastoma. Journal of Korean Medical Science. https://doi.org/10.3346/jkms.2026.41.e130

Vancouver

Han MH, Noh YK, Kim H, Kim KS, Kim DH, Jung US, et al. Multi-Omics and Machine Learning Analyses Reveal PIK3CG, PRKCD, and TRIM22 as Potential Markers of Poor Prognosis and Immune Activation in Glioblastoma. Journal of Korean Medical Science. 2026. doi:10.3346/jkms.2026.41.e130

BibTeX
@article{Han2026,
  author = {Han, Myung-Hoon and Noh, Yung-Kyun and Kim, Hyunkee and Kim, Kyu Shik and Kim, Dong-Hoon and Jung, Un Suk and Lee, Kyung Suk and Kwon, Mi Jung and Chae, Seoung Wan and Min, Kyueng-Whan},
  title = {Multi-Omics and Machine Learning Analyses Reveal PIK3CG, PRKCD, and TRIM22 as Potential Markers of Poor Prognosis and Immune Activation in Glioblastoma},
  journal = {Journal of Korean Medical Science},
  year = {2026},
  doi = {10.3346/jkms.2026.41.e130}
}
Kostenlos starten →